Long-term outcomes of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer: a prospective phase II study - Report - MDSpire
Advertisement
Long-term outcomes of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer: a prospective phase II study
Clinical Report: Long-term Results of Definitive Chemoradiotherapy Using DCF-RT
Overview
This phase II study evaluates the efficacy and safety of definitive chemoradiotherapy (CRT) using docetaxel, cisplatin, and 5-fluorouracil (DCF) for postoperative locoregional recurrence of esophageal cancer. The findings indicate a median progression-free survival of 48 months and overall survival rates of 75.2% at 3 years and 58.8% at 5 years.
Background
Postoperative locoregional recurrence of esophageal cancer poses significant treatment challenges, with conventional therapies yielding unsatisfactory outcomes. The study investigates a novel DCF-RT regimen. Understanding the efficacy and safety of this approach is crucial for enhancing patient management strategies.
Data Highlights
Outcome
Result
Median Progression-Free Survival
48.0 months
3-Year Progression-Free Survival Rate
55.2%
5-Year Progression-Free Survival Rate
49.7%
3-Year Overall Survival Rate
75.2%
5-Year Overall Survival Rate
58.8%
Key Findings
The median observation period for survivors was 77.5 months.
89.7% of patients completed the planned treatment regimen without dose reduction.
Grade 4 hematologic toxicities were observed in 3 patients.
One patient experienced grade 3 heart failure.
No grade ≥2 late adverse events were reported.
Clinical Implications
The DCF-RT regimen demonstrates a significant improvement in progression-free and overall survival for patients with postoperative locoregional recurrence of esophageal cancer.
Conclusion
The results indicate that DCF-based chemoradiotherapy may provide improved survival outcomes in patients with postoperative locoregional recurrent esophageal cancer.
